Telix Pharmaceuticals (ASX:TLX): Q3 2026 Revenue and Radiopharmaceutical Milestones

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Telix Pharmaceuticals (ASX:TLX): Q3 2026 Revenue and Radiopharmaceutical Milestones

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix Pharmaceuticals (ASX:TLX) reported USD 245 million Q3 2026 revenue.
Precision Medicine Revenue rose 30% to USD 201 million.
The FDA approved Pixclara for glioma imaging in 2026.
TLX shares traded at AUD 13.71 on 12 November 2026, down 2.21%.

Telix Pharmaceuticals Limited (ASX:TLX) develops and commercialises diagnostic and therapeutic radiopharmaceutical products used in oncology and related medical care. Its shares stood at AUD 13.71 on 12 November 2026, down 2.21% for the session. An October financial update for the September quarter reported higher year-on-year revenue, commercial activity in prostate imaging and additional regulatory and clinical milestones, while several development programs remained incomplete.

Precision Medicine and Therapeutics

Telix Pharmaceuticals (ASX:TLX) operates commercial molecular-imaging products and research programs focused on targeted radiopharmaceutical therapies. Its prostate-specific membrane antigen positron emission tomography imaging portfolio includes Illuccix and Gozellix. The company also operates Manufacturing and distribution capabilities through Telix Manufacturing Solutions. Commercial sales depend on product authorisations, production availability, reimbursement and clinical adoption. Development-stage therapeutic products are subject to trial results and regulatory requirements and cannot be treated as approved medicines.

September-Quarter Revenue

For the three months ended 30 September 2026, Telix Pharmaceuticals (ASX:TLX) reported group revenue of USD 245 million, up 19% from USD 206 million in the corresponding quarter of 2025. Revenue was slightly below the USD 247 million recorded in the June 2026 quarter. Precision Medicine revenue increased 30% year on year to USD 201 million, supported by Illuccix and Gozellix. Telix Manufacturing Solutions revenue was USD 44 million, compared with USD 47 million a year earlier and USD 45 million in the preceding quarter. The quarterly numbers were described by the company as unaudited.

The company reaffirmed expectations for FY26 revenue and other income exceeding USD 1 billion, with revenue tracking toward the upper end of its USD 950–970 million revenue guidance and an additional USD 40 million of other income. It narrowed its anticipated FY26 Research and Development expenditure range to USD 240–260 million, from USD 230–270 million previously. These figures are guidance, not reported full-year results.

Pixclara and Clinical Development

During 2026, the US Food and Drug Administration approved Pixclara for glioma imaging, with first commercial doses administered in September. Telix Pharmaceuticals (ASX:TLX) also reported completion of enrolment in the Phase 3 BiPASS study evaluating pre-biopsy prostate cancer detection. In its therapeutic pipeline, the company discussed work to progress the ProstACT Global Phase 3 program, with enrolment continuing outside the United States. The Phase 2 OPTIMAL-PSMA study completed enrolment of 120 patients, with a data readout expected in the first half of 2027. Study progress does not establish eventual regulatory approval or treatment effectiveness.

Proposed ITM Combination and Risks

Telix announced a proposed Merger with Isotope Technologies Munich in September 2026, describing potential manufacturing and development integration. It is important to distinguish a transaction announcement from completed integration. The company’s product portfolio is exposed to radiopharmaceutical production logistics, isotope availability, clinical validation, regulatory review, reimbursement and research spending. For Telix Pharmaceuticals (ASX:TLX), additional regulatory submissions and trials can involve delays or changed requirements. Product-specific regulatory status also matters: Illuccix, Gozellix and Pixclara have US approvals, whereas other development products identified in the quarterly announcement had not received Marketing authorisation.

What to Watch Next

Future disclosures may clarify delivery against FY26 guidance, the commercial ramp-up of Pixclara, prostate-imaging Demand and additional regulatory steps for development-stage products. In particular, the company indicated it was preparing a resubmission package concerning the kidney-cancer imaging candidate Zircaix following manufacturing-related observations. Trial recruitment milestones, research spending and progress with the proposed ITM merger are separate monitoring items, each dependent on formal announcements and applicable conditions.

Key Insights

Telix’s September-quarter report showed higher year-on-year group and Precision Medicine revenue, alongside ongoing research expenditure and regulatory activity. The distinction between commercial products, pending applications, Clinical Trials and transaction proposals is essential when interpreting the company’s 2026 developments.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.